Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...

It's been cleared for second-line use in patients who have progressed or are intolerant to hedgehog inhibitor therapy. Libtayo was the sixth PD-L/PD-L1 inhibitor to reach the market, starting out ...

Regeneron UK Limited has announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo (cemiplimab) for use on ...

Moments after Regeneron CEO Len Schleifer scolded analysts for asking too many questions about the disappointing sales of eye ...

Sanofi and Regeneron’s checkpoint inhibitor Libtayo has become the first immunotherapy to improve survival when used as a second-line therapy in cervical cancer, setting up regulatory filings ...

Regeneron stock has trended bearishly since August, but growth in LIBTAYO and DUPIXENT offers a promising outlook, prompting a BUY rating. EYLEA HD's success mitigates biosimilar competition ...

Regeneron's Q4 earnings report shows revenue growth, stable EYLEA sales, dividend announcement, and impressive growth for ...

Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...

The trial evaluates THIO's safety, tolerability, and efficacy in combination with PD-(L)1 inhibition. THIO sequenced with Libtayo extended overall survival in those with non–small cell lung cancer who ...

Immuneering Corporation (IMRX), a clinical-stage oncology company, Thursday said it has signed a clinical supply agreement with ...